HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated LGND | 0.00 |
HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:
LGND) with a Buy and raises the price target from $289 to $358.